Home › Funds › Cormorant Asset Management, LP › AMLX
Cormorant Asset Management, LP position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Cormorant Asset Management, LP reported holding 200,000 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$3.6M, representing 0.18% of its reported portfolio and ranking #46 among its reported holdings. Cormorant Asset Management, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's AMLX position evolved
Cormorant Asset Management, LP first disclosed a stake in AMLX in Q3 2025 at 500,000 shares (US$6.8M). Across 4 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 200,000 shares valued at US$3.6M — a reduction of -150,000 shares quarter over quarter.. Notable position changes include a 43% trim in Q2 2026 (shares rose 62% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 500.00K | $6.79M | New |
| Q4 2025 | 400.00K | $4.83M | Reduce |
| Q1 2026 | 350.00K | $4.87M | Reduce |
| Q2 2026 | 200.00K | $3.59M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Commodore Capital LP 5.65M sh · $101.47M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Siren, L.L.C. 1.48M sh · $26.59M · Q2 2026
- Almitas Capital LLC 974.88K sh · $17.51M · Q2 2026
- Jones Hill Capital LP 894.06K sh · $16.06M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- HighVista Strategies LLC 386.08K sh · $6.93M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held AMLX?
Cormorant Asset Management, LP has disclosed AMLX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Cormorant Asset Management, LP's current position in AMLX?
As of Q2 2026, Cormorant Asset Management, LP holds 200.00K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $3.59M, representing 0.18% of its reported portfolio and ranking #46.
Has Cormorant Asset Management, LP been buying or selling AMLX?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in AMLX.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.